• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

吡罗昔康β-环糊精在大鼠血浆和淋巴中的药代动力学特征。

Pharmacokinetic profile of piroxicam beta-cyclodextrin, in rat plasma and lymph.

作者信息

Kimura E, Bersani-Amado C A, Sudo L S, Santos S R, Oga S

机构信息

Depto de Farmácia e Farmacologia, Universidade de Maringá, Paraná, Brazil.

出版信息

Gen Pharmacol. 1997 May;28(5):695-8. doi: 10.1016/s0306-3623(96)00362-x.

DOI:10.1016/s0306-3623(96)00362-x
PMID:9184804
Abstract
  1. The absorption of piroxicam into the blood of rats is significantly slower after oral administration of piroxicam beta-cyclodextrin than of free piroxicam. 2. The pharmacokinetic profiles of piroxicam in rat lymph were very similar in both groups. 3. Bioavailability of piroxicam in plasma is higher after treatment with the inclusion product than with free piroxicam. On the other hand, bioavailability in lymph is higher when free piroxicam is administered.
摘要
  1. 大鼠口服吡罗昔康β-环糊精后，吡罗昔康在其血液中的吸收明显慢于游离吡罗昔康。2. 两组大鼠淋巴中吡罗昔康的药代动力学特征非常相似。3. 用包合物治疗后，吡罗昔康在血浆中的生物利用度高于游离吡罗昔康。另一方面，给予游离吡罗昔康时，其在淋巴中的生物利用度更高。

相似文献

1
Pharmacokinetic profile of piroxicam beta-cyclodextrin, in rat plasma and lymph.吡罗昔康β-环糊精在大鼠血浆和淋巴中的药代动力学特征。
Gen Pharmacol. 1997 May;28(5):695-8. doi: 10.1016/s0306-3623(96)00362-x.
2
Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta-cyclodextrin, in healthy subjects under single dose and steady-state conditions.吡罗昔康与β-环糊精包合物CHF1194在健康受试者单剂量和稳态条件下的口服生物利用度。
Eur J Clin Pharmacol. 1995;47(6):531-6. doi: 10.1007/BF00193707.
3
Supermolecular inclusion of piroxicam with beta-cyclodextrin: pharmacokinetic properties in man.吡罗昔康与β-环糊精的超分子包合物：人体药代动力学特性
Eur J Rheumatol Inflamm. 1993;12(4):12-28.
4
Piroxicam concentrations in plasma and synovial fluid after a single dose of piroxicam-beta-cyclodextrin.单次服用吡罗昔康-β-环糊精后血浆和滑液中的吡罗昔康浓度。
Int J Clin Pharmacol Ther. 2001 Jan;39(1):33-6. doi: 10.5414/cpp39033.
5
Comparative population pharmacokinetic-pharmacodynamic analysis for piroxicam-beta-cyclodextrin and piroxicam.吡罗昔康-β-环糊精与吡罗昔康的比较群体药代动力学-药效学分析。
J Clin Pharmacol. 2000 Nov;40(11):1257-66.
6
Piroxicam-beta-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states.吡罗昔康-β-环糊精。对其药效学和药代动力学特性以及在风湿性疾病和疼痛状态中的治疗潜力的综述。
Drugs. 1994 Dec;48(6):907-29. doi: 10.2165/00003495-199448060-00007.
7
Supermolecular inclusion of piroxicam with beta-cyclodextrin: a review of its pharmacological properties in laboratory animals.吡罗昔康与β-环糊精的超分子包合物：实验室动物药理特性综述
Eur J Rheumatol Inflamm. 1993;12(4):6-11.
8
Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effect.吡罗昔康与β-环糊精的包合物及其在阳离子微乳中的包封。体外药物释放和体内局部抗炎作用。
Int J Pharm. 2001 Jul 3;222(1):45-55. doi: 10.1016/s0378-5173(01)00692-5.
9
Solid-state dependent dissolution and oral bioavailability of piroxicam in rats.固体状态依赖性溶解和吡罗昔康在大鼠体内的口服生物利用度。
Eur J Pharm Sci. 2013 Jan 23;48(1-2):47-54. doi: 10.1016/j.ejps.2012.10.005. Epub 2012 Oct 22.
10
Cross-over study of the bioavailability of a new NSAID (droxicam) versus piroxicam in healthy volunteers following single and multiple dose administration.一项关于新型非甾体抗炎药（屈昔康）与吡罗昔康在健康志愿者单次及多次给药后生物利用度的交叉研究。
Eur J Drug Metab Pharmacokinet. 1992 Jul-Sep;17(3):195-9. doi: 10.1007/BF03190145.

引用本文的文献

1
Conjugates of methylated cyclodextrin derivatives and hydroxyethyl starch (HES): Synthesis, cytotoxicity and inclusion of anaesthetic actives.甲基化环糊精衍生物和羟乙基淀粉（HES）的缀合物：合成、细胞毒性和麻醉活性物质的包合。
Beilstein J Org Chem. 2014 Dec 19;10:3087-96. doi: 10.3762/bjoc.10.325. eCollection 2014.